The Food and Drug Administration has granted Fast Track designation to AMX0114 for the treatment of amyotrophic lateral sclerosis (ALS).

Researchers have developed a gene therapy that significantly slowed motor function loss in preclinical models of amyotrophic ...

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best biotech stocks to invest in now. On June 3, Amylyx ...

The experimental ALS treatment usnoflast exhibited promising signs of slowed functional decline and improved breathing in a ...

In addition to these symptoms, systemic sclerosis can affect internal organs, such as the lungs and kidneys, with serious consequences. We know that immune dysregulation causes vascular damage and ...

Scientists at the Baylor College of Medicine and collaborating institutions used complementary approaches that integrate exome sequencing and evolutionary action machine learning to identify ...

In 2024, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress celebrated a remarkable 40 years of pioneering work. Regional committees have emerged around the ...

Systemic sclerosis (SSc) is a severe autoimmune disease with complex genetic causes. Some genetic contributors have been identified, but others remain unknown, which has impeded development of ...

The onset of amyotrophic lateral sclerosis (ALS) is conventionally considered as commencing with the recognition of clinical symptoms. We propose that, in common with other neurodegenerations, the ...

On April 22, 2025, the ALS Association and other advocacy groups (describing themselves as “the collective voice of the ALS community across the United States”) sent a letter to the ALS Congressional ...

DAZALS trial missed its main goal, but patients on 300 mg dazucorilant had significantly improved survival at 24 weeks. ROSELLA trial met its endpoint, showing a 30% reduced risk of progression in ...